Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer
- PMID: 15112354
- PMCID: PMC4622778
- DOI: 10.3748/wjg.v10.i9.1337
Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer
Abstract
Aim: To study the value of monitoring K-ras point mutation at codon 12 and telomerase activity in exfoliated cells obtained from pancreatic duct brushings during endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of pancreatic cancer.
Methods: Exfoliated cells obtained from pancreatic duct brushings during ERCP were examined in 27 patients: 23 with pancreatic cancers, 4 with chronic pancreatitis. K-ras point mutation was detected with the polymerase chain reaction and restriction fragment-length polymorphism (PCR-RFLP). Telomerase activity was detected by PCR and telomeric repeat amplification protocol assay (PCR-TRAP-ELISA).
Results: The telomerase activities in 27 patients were measured in 21 exfoliated cell samples obtained from pancreatic duct brushings. D450 value of telomerase activities in pancreatic cancer and chronic pancreatitis were 0.446+/-0.27 and 0.041+/-0.0111, respectively. Seventy-seven point eight percent (14/18) of patients with pancreatic cancer and none of the patients with chronic pancreatitis showed telomerase activity in cells collected from pancreatic duct brushings when cutoff value of telomerase activity was set at 2.0. The K-ras gene mutation rate (72.2%) in pancreatic cancer was higher than that in chronic pancreatitis (33.3%) (P<0.05). In considering of both telomerase activities and K-ras point mutation, the total positive rate was 83.3%(15/18), and the specificity was 100%.
Conclusion: Changes of telomerase activities and K-ras point mutation at codon 12 may be an early event of malignant progression in pancreatic cancer. Detection of telomerase activity and K-ras point mutation at codon 12 may be complementary to each other, and is useful in diagnosis of pancreatic cancer.
Figures


Similar articles
-
Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutation.Gastrointest Endosc. 2000 Jun;51(6):708-13. doi: 10.1067/mge.2000.104654. Gastrointest Endosc. 2000. PMID: 10840305
-
Diagnosis of pancreatic cancer by cytology and telomerase activity in exfoliated cells obtained by pancreatic duct brushing during endoscopy.Hepatobiliary Pancreat Dis Int. 2007 Jun;6(3):308-11. Hepatobiliary Pancreat Dis Int. 2007. PMID: 17548257
-
Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours.Gut. 1995 May;36(5):781-7. doi: 10.1136/gut.36.5.781. Gut. 1995. PMID: 7797131 Free PMC article.
-
Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas.Hepatogastroenterology. 1999 Jan-Feb;46(25):532-9. Hepatogastroenterology. 1999. PMID: 10228857 Review.
-
[Mutation of the K-ras oncogene in pancreatic carcinoma, and application of its detection in pancreatic juice to diagnose pancreatic carcinoma].Nihon Rinsho. 1995 Feb;53(2):511-7. Nihon Rinsho. 1995. PMID: 7699881 Review. Japanese.
Cited by
-
Diagnosis and management of relapsing pancreatitis associated with cystic neoplasms of the pancreas.World J Gastroenterol. 2008 Feb 21;14(7):1038-43. doi: 10.3748/wjg.14.1038. World J Gastroenterol. 2008. PMID: 18286685 Free PMC article. Review.
-
Understanding, diagnosing, and treating pancreatic cancer from the perspective of telomeres and telomerase.Cancer Gene Ther. 2024 Sep;31(9):1292-1305. doi: 10.1038/s41417-024-00768-6. Epub 2024 Apr 9. Cancer Gene Ther. 2024. PMID: 38594465 Free PMC article. Review.
-
Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.World J Gastroenterol. 2007 Jul 21;13(27):3714-20. doi: 10.3748/wjg.v13.i27.3714. World J Gastroenterol. 2007. PMID: 17659731 Free PMC article.
References
-
- Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepatogastroenterology. 2001;48:933–938. - PubMed
-
- Yoshizawa K, Nagai H, Sakurai S, Hironaka M, Morinaga S, Saitoh K, Fukayama M. Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas. Virchows Arch. 2002;441:437–443. - PubMed
-
- Raimondo M, Tachibana I, Urrutia R, Burgart LJ, DiMagno EP. Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol. 2002;97:2553–2558. - PubMed
-
- Nakata B, Yashiro M, Nishioka N, Aya M, Yamada S, Takenaka C, Ohira M, Ishikawa T, Nishino H, Wakasa K, et al. Genetic alterations in adenoma-carcinoma sequencing of intraductal papillary-mucinous neoplasm of the pancreas. Int J Oncol. 2002;21:1067–1072. - PubMed
-
- Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002;9:39–44. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous